Latham & Watkins Advises GoodCell in US$17.9 Million Preferred Equity Round

A Boston-based Emerging Companies team is advising the company decoding human health to extend and improve the quality of life through technology powered by science.

November 17, 2020

GoodCell (LifeVault Bio), the company decoding human health to extend and improve the quality of life through technology powered by science, has announced that it has raised US$17.9 million in a preferred equity financing round. GoodCell intends to use this latest funding to continue the development of its technology for detecting and monitoring accumulated genetic variation within blood cells. The financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and its personal biobanking service.

Latham & Watkins LLP represented GoodCell in the transaction with a Boston-based corporate deal team led by partner John Chory and associates Spencer Ricks and Belinda King.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.